Highlights

  • Five analysts currently assign a consensus Hold rating to TLSI shares.
  • Recent brokerage updates reflect rating changes and revised price targets.
  • Institutional investors adjusted holdings following quarterly earnings disclosure.

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) are presently covered by five research firms, resulting in a consensus recommendation of Hold. The current analyst mix includes one Sell rating, one Hold rating, and three Buy ratings. Based on updates issued over the past year, the average twelve-month price target across covering brokerages stands at USD 11.00.

Several firms have recently revised their views on the stock. Canaccord Genuity Group increased its price target from USD 11.00 to USD 12.00 in a research update issued on December 17 while maintaining a Buy rating. Wall Street Zen adjusted its rating from Sell to Hold in late November. Zacks Research also revised its stance, moving from Strong Sell to Hold in mid-December. In contrast, Weiss Ratings reaffirmed its Sell (D-) rating earlier in the month.

Institutional activity in TriSalus Life Sciences reflected several position changes during recent quarters. Nantahala Capital Management LLC increased its holdings by approximately 2.0% during the third quarter, bringing its total ownership to just over 2.04 million shares. AWM Investment Company Inc. initiated a new position in the second quarter valued at roughly USD 6.8 million. Vanguard Group Inc. expanded its stake by more than 42% during the third quarter, while Gilder Gagnon Howe & Co. LLC raised its holdings by about 32% in the second quarter. Geode Capital Management LLC more than doubled its position over the same period. Collectively, institutional investors hold approximately 2.58% of the company’s outstanding shares.

TriSalus Life Sciences reported its latest quarterly results on November 13. The company posted a loss of USD 0.96 per share, compared with consensus expectations of a USD 0.17 loss. Quarterly revenue was reported at USD 11.57 million, slightly below analyst estimates of USD 11.76 million. Analysts currently expect the company to record a full-year loss of around USD 1.55 per share.

Shares of TLSI last traded at USD 6.87 on December 24, 2025.